TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01941368

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB-FA
Study: NCT02569229

Intervention type: OTHER
Intervention: Diagnostics for glucose tolerance with 3 different methods.
Description: 1. A 7-day course of subcutaneous continuous glucose monitoring system (CGMS).~2. An oral glucose tolerance test done within the 7 day period of CGMS.~3. Optionally a intravenous glucose tolerance test done within the 7 day period of CGMS.
Study: NCT01807819

Intervention type: OTHER
Intervention: Heart Failure
Description: Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
Study: NCT03213041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04742244

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lvemon verbena extract
Description: Each capsule contained 200 mg of lemon verbena extract 2 capsules/day, 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: Each capsule contained 0 mg of lemon verbena extract 2 capsules/day, 14 days
Study: NCT02956291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Fingerprinting
Description: Non-contrast MRF acquisition will be acquired through the region of tumor in all patients. For patients receiving intravenous gadolinium based contrast, a post contrast MRF acquisition will also be acquired. This acquisition will be skipped in patients who do not receive or are not eligible for receiving IV contrast as a part of their clinical scan. The research scan will take approximately 10-15 minutes
Study: NCT01941368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: High Intensity Interval Training
Study: NCT02851199

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalography
Description: Electroencephalograph recording following hyperventilation in different participant's body postures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalography
Description: Electroencephalograph recording following hyperventilation in different participant's body postures
Study: NCT03272646

Intervention type: PROCEDURE
Intervention: surgery
Description: gastric resection or total gastrectomy

Intervention type: PROCEDURE
Intervention: surgery
Description: gastric resection or total gastrectomy

Intervention type: PROCEDURE
Intervention: surgery
Description: gastric resection or total gastrectomy
Study: NCT02081365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Dental Anxiety Treatment
Description: The Computerized Dental Anxiety Treatment Program consists of treatment modules that are be delivered through a computer. The modules use Cognitive Behavioral Therapy (CBT) to assist the participant in preparing a personal plan for managing his/her dental anxiety. The program incorporates a range of CBT techniques, including cognitive restructuring, exposure, and motivational interviewing.
Study: NCT01559090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-546
Description: Stage I: 100 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-546
Description: Stage I: 300 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-546
Description: Stage I: 1000 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 1000 mg IV, multiple doses once every 4 wks for 156 wks, the dose at Stage II was changed to 300 mg IV.
Study: NCT02733107

Intervention type: DRUG
Group type: OTHER
Intervention: Apatinib
Description: Apatinib, 250mg daily, po, continue until disease progression

Intervention type: DRUG
Group type: OTHER
Intervention: Etoposide
Description: Etoposide, 50mg daily, po, day 1 to day 20, repeat Q 4 weeks until disease progression
Study: NCT02653274

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast porridge
Description: 220 kcal breakfast porridge served with 240 mL glass of water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast porridge
Description: 220 kcal breakfast porridge served with 240 mL glass of water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast porridge
Description: 220 kcal breakfast porridge served with 240 mL glass of water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast porridge
Description: 220 kcal breakfast porridge served with 240 mL glass of water
Study: NCT02207361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Carboplatin
Description: Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel, Epirubicin
Description: Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
Study: NCT02023203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Totally Extraperitoneal laparoscopic inguinal hernia repair
Description: Laparoscopic hernioplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Totally Extraperitoneal laparoscopic inguinal hernia repair
Description: Laparoscopic hernioplasty
Study: NCT01781702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelubiprofen 30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex 200 mg
Study: NCT02239185

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hernial sac ligation in continuity
Description: Laparoscopic closure of hernia sac at internal inguinal ring in continuity using 3 - 0 non-absorbable purse-string suture. The spermatic vessels and vas deferens are well visualized and protected during the suture. In all cases, hydro dissection can be done by injection of saline to separate the peritoneum from cord structures. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying. The stitches included the peritoneum and the underlying muscular tissue lateral to the spermatic cord. The procedure is modified in children with a dilated internal ring.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hernial sac disconnection
Description: Circumferential incision on the peritoneum at IIR will be started to separate hernia sac from the peritoneum. Initial disconnection of the vas and vessels will be done and then the peritoneum posterior to the internal ring will be divided and then the anterior disconnection will be carried out. Saline can be injected to separate the peritoneum from cord structures (hydro dissection). Care is taken not to damage the vas and vessels by handling them. Then the proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
Study: NCT04519814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: selective laser trabeculoplasty (SLT)
Description: Treatment will be performed on Day 0 using the VISULAS green with Option CSLT for SLT treatment and a mirror goniolens to visualize the trabecular meshwork. The initial energy level is set according to the grade of angle pigmentation and bubble formation. Approximately one hundred non-overlapping lesions will be applied in a single session to 360° of the trabecular meshwork.
Study: NCT04136028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kineret
Description: Kineret at a dose of 8 mg/kg per day subcutaneously daily, every day at the same time
Study: NCT03356067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric endoscopic peroral pyloromyotomy
Description: G-POEM is, in principle, adaptation of POEM (per-oral endoscopic myotomy) in the stomach. The procedure consists of:~1. Mucosal incision at the greater curvature 3-5 cm from the pylorus~2. Submucosal tunnelling~3. Finding pyloric sphincter~4. Myotomy (2-3 cm) of the pyloric muscle~5. Incision closure (endoclips or suture device)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Esophago-gastro-duodenoscopy
Description: Standard endoscopic examination of the upper GI tract with flexible endoscope
Study: NCT00052559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo external beam radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03564275

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Boost
Description: 13-15 treatments with proton therapy given as a boost to standard of care photon therapy
Study: NCT00219401

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pneumococcal 7 valent conjugate vaccine (Prevenar®)
Description: Accelerated PCV vaccinaton.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7 valent conjugate vaccine (Prevenar®)
Description: Accelerated PCV vaccinaton.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7 valent conjugate vaccine (Prevenar®)
Description: Accelerated PCV vaccinaton.
Study: NCT03693222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride
Description: The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride
Description: The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
Study: NCT02942147

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
Study: NCT02793908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pleyris
Description: Luteal phase will be supplemented starting by the ovulation day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crinone8
Description: Luteal phase will be supplemented starting by the ovulation day for 14 days
Study: NCT02099799

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer and Website
Description: Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
Study: NCT03431675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Single-dose oral ciprofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Single-dose oral ciprofloxacin
Study: NCT03037957

Intervention type: DEVICE
Intervention: ARIES Group A Strep Assay
Study: NCT02859545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Validation Training for Romantic Partners
Description: In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to validate the individual with chronic pain's pain-related distress and given education about validation. This involves an approximately 45-minute brief, interactive training.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Chronic Pain Education Training for Romantic Partners
Description: In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to ask health professionals questions about treatment options and given health education about chronic pain. This involves an approximately 45-minute brief, interactive training.
Study: NCT00840645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: Oral
Study: NCT01070784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler (Budesonide/formoterol)
Description: 2 x 160/4.5 microgram, inhalation, bid, 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: any available COPD treatment; investigator to decide
Description: According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
Study: NCT01641315

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rabies vaccine
Description: Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.~Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.~Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.~Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.~Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.~Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.~Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0.
Study: NCT01704248

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Eye Drop Guide technique
Description: 1. Wash the hands.~2. Shake and then uncap the bottle.~3. Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~4. Use the lower lip of the cup to pull the lower lid down like what they normally do with the fingers.~5. Then place the upper lip down to cover the whole orbital rim area.~6. Tilt the head back if seated or standing.~7. Insert the bottle in the device all the way. Hold the bottle gently.~8. Look upward.~9. Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~10. Close the eye 2-3 minutes.~For the non-seeing eye (best-corrected visual acuity ≤ 20/400) the participants should insert the bottle in the device before cover the eye then proceed with head tilt and look upward.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine self-instillation technique
Description: 1. Wash the hands.~2. Shake and then uncap the bottle.~3. Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~4. Lie down or tilt the head back if seated or standing.~5. Using the other hand, pull the lower lid down.~6. Hold the bottle over the eye and look up.~7. Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~8. Close the eye 2-3 minutes.~For the participants using more than one medication after instilling one bottle the participants should wait 3-5 minutes between administering different medications in the same eye.
Study: NCT04467021

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual blood pressure management
Study: NCT03064620

Intervention type: BIOLOGICAL
Intervention: PCV
Description: PCV7 was introduced in Israel (IL and EJ) in July 2009 PCV13 replaced PCV7 in IL and EJ on Oct 2010 PCV10 was introduced in PA in 2011
Study: NCT04474145

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comb group
Description: Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection.
Study: NCT04467021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Pressure Measurement
Description: Undergo blood pressure measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Management
Description: Undergo intensive systolic BP management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03520023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Consult
Description: Consult of hospital palliative care service for those meeting study inclusion criteria
Study: NCT00426751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Description: Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
Study: NCT01185535

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: times of topical anesthesia for glottis
Description: topical anesthesia with pressure nebulized 2% lidocaine for glottis either two times or three times or four times

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: times of topical anesthesia for glottis
Description: topical anesthesia with pressure nebulized 2% lidocaine for glottis either two times or three times or four times

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: times of topical anesthesia for glottis
Description: topical anesthesia with pressure nebulized 2% lidocaine for glottis either two times or three times or four times
Study: NCT02244359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Study: NCT06128824

Intervention type: OTHER
Intervention: MR Imaging
Description: Serial magnetic resonance imaging (MRI)

Intervention type: OTHER
Intervention: MR Imaging
Description: Serial magnetic resonance imaging (MRI)
Study: NCT02235753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training, short interval
Description: The intensity of HIT-S sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 100% which will be the target intensity from 6 to 12 months. The protocol includes four 6 min sets consisting of 15 sec exercise followed by 15 sec passive recovery separated with 3 min passive recovery between sets. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 15 seconds exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-S patients with ECG monitoring and supervised by physician.